New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.
BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated with glufosfamide. The study revealed four patient clusters, with one ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...
Ibex's high-performance AI platform--already deployed across more than 50 health systems worldwide and used in collaboration with major industry organizations such as Philips and Roche--now supports ...
Liver cancer remains one of the deadliest cancers worldwide, something that escapes early detection. Understand liver cancer, ...
Researchers identify APOC1 and NOP16 as promising prostate cancer biomarkers that could aid early diagnosis. Learn more about ...
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into ...
Despite the clinical utility of biomarker testing in patients with prostate cancer, the tests are infrequently ordered, preventing optimized care. Despite guideline recommendations and the efficacy of ...
Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...
A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback